Study to Evaluate the Safety and Efficacy of Treatment with NLM-001 before Standard Chemotherapy plus Zalifrelimab in Patients with Advanced Pancreatic Cancer

2024-518852-22-00 Human pharmacology (Phase I) - Other Ended

Start 3 Sep 2021 · End 28 Apr 2025 · Status Ended · 1 EU/EEA countries · 6 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 28
Countries 1
Sites 6

Advanced Pancreatic Cancer

Key facts

Sponsor
Nelum Corp.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
3 Sep 2021 → 28 Apr 2025
Decision date (initial)
2024-10-23
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-518852-22-00
EudraCT number
2020-004932-52
ClinicalTrials.gov
NCT04827953

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Pancreatic Cancer

VersionLevelCodeTermSystem organ class
27.0 LLT 10033605 Pancreatic cancer metastatic 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Nelum Corp.

Sponsor organisation
Nelum Corp.
Address
5000 Centre Green Way Suite 500
City
Cary
Postcode
27513-5821
Country
United States

Scientific contact point

Organisation
Nelum Corp.
Contact name
Clinical Operations Department

Public contact point

Organisation
Nelum Corp.
Contact name
Clinical Operations Department

Locations

1 EU/EEA country · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 28 6
Rest of world 0

Investigational sites

Spain

6 sites · Ended
Complexo Hospitalario Universitario De Santiago
Oncologia, Calle Choupana Da S/n, 15706, Santiago De Compostela
Hospital Universitario Marques De Valdecilla
Oncología, Avenida Valdecilla Sn, 39008, Santander
Hospital Universitari Vall D Hebron
Gastrointestinal and endocrine tumor unit, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Donostia
Oncologia, Pasealeku Doct. Begiristain 109, 20014, Donostia
Hospital Universitario Virgen De La Victoria
Oncologia, Calle Del Arroyo Teatinos S/N, 29010, Malaga
Hospital Universitario Miguel Servet
Medical Oncology, Paseo De Isabel La Catolica 1-3, 50009, Zaragoza

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2021-09-03 2025-04-28 2021-10-01 2024-05-03

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-09 Spain Acceptable
2024-10-23
2024-10-23
2 SUBSTANTIAL MODIFICATION SM-2 2025-03-17 Spain Acceptable
2025-05-23
2025-05-23